(0.65%) 5 051.08 points
(0.60%) 38 131 points
(1.14%) 15 783 points
(0.37%) $79.29
(5.43%) $2.04
(-0.04%) $2 310.00
(0.26%) $26.82
(0.87%) $963.25
(0.01%) $0.933
(-0.26%) $11.00
(0.05%) $0.799
(-1.36%) $91.99
@ $8.45
Išleistas: 14 vas. 2024 @ 16:30
Grąža: 8.40%
Ankstesnis signalas: vas. 13 - 20:42
Ankstesnis signalas:
Grąža: 1.38 %
Live Chart Being Loaded With Signals
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia...
Stats | |
---|---|
Šios dienos apimtis | 155 906 |
Vidutinė apimtis | 403 190 |
Rinkos kapitalizacija | 441.19M |
EPS | $0 ( 2024-02-26 ) |
Kita pelno data | ( $-0.190 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -9.16 |
ATR14 | $0.00900 (0.10%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Winningham Rick E | Buy | 300 000 | Ordinary Shares |
2024-04-02 | Sawaf Aziz | Buy | 100 000 | Ordinary Shares |
2024-04-02 | Miller Aine | Buy | 37 500 | Ordinary Shares |
2024-04-02 | Grimaud Brett A. | Buy | 100 000 | Ordinary Shares |
2024-04-02 | Farnum Rhonda | Buy | 37 500 | Ordinary Shares |
INSIDER POWER |
---|
47.03 |
Last 95 transactions |
Buy: 1 532 401 | Sell: 647 888 |
Tūris Koreliacija
Theravance Biopharma Inc Koreliacija
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Theravance Biopharma Inc Koreliacija - Valiuta/Žaliavos
Theravance Biopharma Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $57.42M |
Bruto pelnas: | $51.37M (89.46 %) |
EPS: | $-1.000 |
FY | 2023 |
Pajamos: | $57.42M |
Bruto pelnas: | $51.37M (89.46 %) |
EPS: | $-1.000 |
FY | 2022 |
Pajamos: | $51.35M |
Bruto pelnas: | $44.76M (87.17 %) |
EPS: | $-1.260 |
FY | 2021 |
Pajamos: | $55.31M |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.87 |
Financial Reports:
No articles found.
Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.